Get started

Signalservice

TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
DOGE & ELON The price of Dogecoin is $0.09 today with a 24hour trading volume of 770 million dollar . This represents a 10% price increase since last week and 22% price increase since last month Musk's tweet offering 1 million Dogecoin to anyone who could prove ownership of an emerald mine has led to gains of 4.9% and who can forget when he changed the Twitter logo to feature the Shiba Inu dog, which caused another 30% pump while Dogecoin's technical structure is bullish, there is a lack of buying pressure behind the coin. traders should be cautious and consider waiting for a break in structure on lower timeframes before seeking to enter short positions. daily active addresses have increased as social media buzzed about Dogecoin, but the 90-day mean coin age has been sliding downward since mid-March. Dogecoin bounced off the moving averages on April 12, as seen from the long tail on the day’s candlestick. The bulls tried to drive the DOGE/USDT pair above the 38.2% Fibonacci retracement level of $0.09 but the bears did not budge. This suggests that the sentiment remains negative and traders are selling on rallies. Buyers must push and sustain the price above $0.09 to indicate that the selling pressure may be reduced. The pair may then ascend to the 61.8% retracement level of $0.10. Usually, a break and close above this level results in a 100% retracement. If that happens, the pair may soar to $0.11.
by moonypto
11
Btc/UsdtBITSTAMP:BTCUSD The current price of Bitcoin is $94,242, and the market is at a critical juncture. 🔍 Support and Resistance Levels 1. Support at $94,242: If Bitcoin holds this level, it could signify strong buying pressure. Traders often see this as a crucial area for bulls to defend. Holding above $94,242 could encourage more buyers to enter, fueling the next leg upward. 2. Next Support at $85,000: If Bitcoin breaks below $94,242, the next key support level is $85,000. This level represents a significant area where buyers may step in to prevent further decline. A drop to this level might shake weak hands but also attract long-term investors looking for a discount. 📈 Resistance Levels 1. Resistance at $100,000: If Bitcoin holds $94,242 and the bulls take control, the next target is the psychological and technical resistance at $100,000. This level is highly significant because it’s a round number that could trigger profit-taking by some traders. Breaking this resistance could pave the way for even higher levels. 💡 Summary • If Bitcoin holds $94,242 → next resistance: $100,000 🚀 • If Bitcoin breaks below $94,242 → next support: $85,000 📉 ⚠️ Not financial advice! Always do your research before making trading decisions and manage your risk wisely.
BITSTAMP:BTCUSDLong
by Wolftrader1337
Lingrid | EURUSD Intraday Selling OPPORTUNITY The price perfectly fulfilled my last idea. It hit the target. FX:EURUSD made a downward impulse move, creating a large bearish candle. The market is currently consolidating, providing an opportunity to take advantage of its sideways movement. It is rolling back towards a resistance zone and an upward trendline. Looking left, we see that the price has bounced off this area twice before, so it could potentially rebound again given the current sideways trend. I expect the price to reject the resistance zone, leading to a decline. My goal is support zone around 1.03800 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
5
Lingrid | SUIUSDT possible Sell-Off at the Dawn of 2025BINANCE:SUIUSDT is currently consolidating after reaching the psychological level at 5.00. It’s been moving back and forth, forming lower highs while bouncing off the trendline. The last two weeks of December and the first two weeks of January were characterized by sideways movement last year, and it appears we may be experiencing a similar situation now. It’s important to note that there was a strong bullish impulse leg before, but the price failed to continue moving higher, indicating a lack of bullish momentum to sustain that upward movement. This suggests that we might see some bearish action in the near term, potentially setting the stage for a stronger bullish move later on. I expect the market to retest at least channel border. My goal is support zone around 3.61 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
5
Lingrid | EURUSD continues to SEE ConsolidationLast week, FX:EURUSD bounced off the resistance zone at 1.04400 and moved lower, but it didn’t have enough bearish momentum to keep going down. Instead, it returned to the level it was at the previous Monday, creating an equal high. I believe the market will push a little higher before pulling back and continuing its bearish move. However, since many markets are in consolidation due to the holidays, there's a chance this week could be another sideways week. Nevertheless, I expect the price to rise above the EQHs before eventually falling. My goal is support zone around 1.03830 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
2
Lingrid | Gold Weekly Market Outlook: Ongoing ConsolidationOANDA:XAUUSD market spent another week in the consolidation zone, oscillating between key levels before bouncing off 2630 and pulling back. During the holiday-shortened week, trading volume was naturally reduced, and the market is now testing a crucial support level. The current market structure suggests a slightly bearish sentiment, particularly after breaking and closing below the previous higher low at 2605 last week. On the weekly timeframe, price action formed another doji candle, suggesting a potential breakout from either its high or low next week. Price continues to trade within the previous week's range between 2585 and 2665. The final monthly candle of 2024 may close as a bearish candle with a long tail, indicating the possibility of a deeper pullback. With relatively few high-impact news next week, the market is likely to continue moving sideways for the next couple of weeks. We can expect increased market noise until we see a clear trend. However, if price breaks below the previous support at 2585, the price may drop to 2500. While the long-term uptrend remains intact, the market appears poised for a continued pullback in the short term. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDShort
by Lingrid
12
Lingrid | BITCOIN complex PULLBACK in the MARKETBINANCE:BTCUSDT is forming a complex ABCD pullback. The price continues to stay below the key level of $100,000, and it has created a range zone with equal lows. Notably, there is a structure shelf around $91,000, where the price has consistently bounced back. On the weekly timeframe, we've seen a bearish long-tailed bar, suggesting that the price may retest $85,000. At the start of 2025, we might experience some market shakeouts, so I expect a deeper pullback before rebounding off the support level, potentially taking liquidity below the structure support. My goal is resistance zone around 98,000 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
1
Lingrid | WIFUSDT a chance to BUY the Pullback The price perfectly fulfilled my last idea. It hit the target zone. BINANCE:WIFUSDT has pulled back significantly from $4.00 level, showing a 65% correction. The price is currently testing the support zone below $2.00 and the boundary of the channel. Given this steep correction, I believe it may be a great opportunity to buy. I expect the market to rise after bouncing off the support level and channel boundary. My goal is resistance zone around $3.00 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
1
EURCAD BUY| Idea Trading AnalysisEURCAD is moving in an ascending channel. The chart broke through the dynamic resistance, which now acts as support. We expect a decline in the channel after testing the current level. We expect a decline in the channel after testing the current level Hello Traders, here is the full analysis. I think we can soon see more fall from this range! GOOD LUCK! Great BUY opportunity EURCAD I still did my best and this is the most likely count for me at the moment. ------------------- Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad ⚜️
Long
by TheGrove
1
Lingrid | GOLD phase of STAGNATION PersistsOANDA:XAUUSD is still moving sideways after the recent bearish move. It is currently testing the resistance zone where it previously dropped after breaking through the upward channel. The last daily candle is a small-range doji, indicating indecision. On the 1H chart, the price action is forming a bearish wedge pattern, which is typically a continuation pattern. If the price remains below the 2630 level, I believe it will retest the upward trendline, leading to further bearish movement. However, if it breaks above this level, the market may move upward to retest the channel's border at 2660. Overall, I expect the wedge pattern to play out. My mid-term goal is support zone around 2560. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDShort
by Lingrid
11
Lingrid | USDCAD selling OPPORTUNITY in the Sideways MARKETFX:USDCAD is currently moving sideways after a bullish trend that began in September. It has encountered a strong resistance zone that was established in March 2020. Therefore it’s possible that the price may consolidate for an extended period following such a strong upward move. At present, price action is trading within the range established in the previous week. The price is forming a clear range, consistently bouncing between the top and bottom levels. I expect the market to continue consolidating, providing opportunities to capitalize on the sideways movement. My goal is support zone around 1.43730 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
1
Lingrid | TONUSDT ongoing Period of MARKET ConsolidationThe price perfectly fulfilled my last idea. It hit the target. OKX:TONUSDT is currently showing a pattern of lower highs and higher lows, indicating that price action is narrowing down, which often suggests a potential breakout. As observed, the market is oscillating between the 5.00 and 6.00 levels, having taken liquidity below the psychological level of 5.00 twice. This may imply that the market is building a range below the 6.00 mark before making a move higher. Given that the price has respected the support level multiple times, I expect it to bounce off this level. If this support holds above it, we could see a gradual move higher, possibly starting in the beginning of next year. My goal is resistance zoen around 6.40 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
1
EurNzd could rise to 1.85On October 1st, EUR/NZD reached a local low at the psychological level of 1.75, followed by a reversal that lasted until November 1st, gaining nearly 1300 pips. A normal correction then occurred, and from mid-November, the pair started consolidating between the 1.78 and 1.80 levels. December brought a breakout above the key 1.80 level, and since then, EUR/NZD has been in a nice uptrend. As of now, the price is 1.8230, and it looks like a breakout above resistance is imminent. In this scenario, the next target for the bulls is the 1.85 level.
Long
by Mihai_Iacob
Gold could close the year in an optimistic toneBefore Christmas, OANDA:XAUUSD established strong support around the 2610 level, maintaining this position even during the low-volume trading days typical of the holiday season. Currently, the price is edging higher, approaching the key resistance zone of 2645–2650. A decisive breakout above this zone could lead to further gains, potentially allowing gold to close the year on a positive and optimistic note, possibly reaching or exceeding the 2700 level. However, a break below the 2610 support would indicate a bearish shift for gold in the near term.
OANDA:XAUUSDLong
by Mihai_Iacob